Difference between revisions of "Interferon alfa-2b (Intron-A)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo")
(35 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.  Mechanism not fully understood.<ref name="insert">[http://www.spfiles.com/piintrona.pdf Interferon alfa-2b (Intron-A) package insert]</ref><ref>[[Media:Interferonalfa-2b.pdf | Interferon alfa-2b (Intron-A) package insert (locally hosted backup)]]</ref><ref>[http://www.introna.com Intron-A manufacturer's website]</ref>
+
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.  Mechanism not fully understood.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103132s5190lbl.pdf Interferon alfa-2b (Intron-A) package insert]</ref><ref>[[:File:Interferonalfa-2b.pdf | Interferon alfa-2b (Intron-A) package insert (locally hosted backup)]]</ref><ref>[http://www.introna.com Intron-A manufacturer's website]</ref>
 
<br>Route: SC, IM, IV, intralesional
 
<br>Route: SC, IM, IV, intralesional
 
<br>Extravasation: no information
 
<br>Extravasation: no information
Line 7: Line 7:
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
−
*[[Chronic myelogenous leukemia]]
+
*[[Adult T-cell leukemia-lymphoma]]
−
*[[Melanoma]]
+
*[[Chronic myeloid leukemia]]
−
*[[Multiple myeloma]]
+
*[[Hairy cell leukemia]]
−
*[[Neuroendocrine tumors]]
+
*[[Kaposi sarcoma]]
 +
*[[Neuroendocrine tumor]]
 
*[[Pancreatic NET]]
 
*[[Pancreatic NET]]
−
*[[Renal cancer]]
+
*[[Renal cell carcinoma]]
 
*[[Systemic mastocytosis]]
 
*[[Systemic mastocytosis]]
  
 
==Diseases for which it was used==
 
==Diseases for which it was used==
 
*[[Follicular lymphoma_-_historical|Follicular lymphoma]]
 
*[[Follicular lymphoma_-_historical|Follicular lymphoma]]
 +
*[[Melanoma - historical|Melanoma]]
 +
*[[Multiple myeloma - historical|Multiple myeloma]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://chemocare.com/chemotherapy/drug-info/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]</ref>
+
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103132s5190lbl.pdf Interferon alfa-2b (Intron-A) package insert]<ref name="insert"></ref>
 +
*[https://chemocare.com/druginfo/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 6/4/1986: Initial FDA approval
+
* 1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with [[hairy cell leukemia]]. ''(Based on Golomb et al. 1988)''
 +
* Uncertain date: Indicated as adjuvant to surgical treatment in patients 18 years of age or older with [[Melanoma|malignant melanoma]] who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. ''(Based on ECOG E1684 & ECOG E1690)''
 +
* Uncertain date: Indicated for the initial treatment of clinically aggressive [[Follicular_lymphoma|follicular Non-Hodgkin’s Lymphoma]] in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin’s Lymphoma has not been demonstrated. ''(Based on GELA GELF-86)''
 +
* Uncertain date: Indicated for the treatment of selected patients 18 years of age or older with [[Kaposi sarcoma|AIDS-Related Kaposi's Sarcoma]]. ''(Based on Lane et al. 1988 & Volberding et al. 1987)''
  
 
==Also known as==
 
==Also known as==
 
'''Caution, may also contain names for interferon beta, interferon gamma, or interferon alfa-2a.'''
 
'''Caution, may also contain names for interferon beta, interferon gamma, or interferon alfa-2a.'''
−
 
+
*'''Brand names:'''
−
{| border="1" style="text-align:center;"
+
{| class="wikitable" style="text-align:center;"
 
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 
|-
 
|-
 
|Advaferon
 
|Advaferon
 
|Alfaferone
 
|Alfaferone
−
|Berofor
 
 
|Biogamma
 
|Biogamma
 
|Canferon A
 
|Canferon A
−
|-
 
 
|Cytoferon
 
|Cytoferon
 
|Egiferon
 
|Egiferon
 
|Feron
 
|Feron
 
|Fiblaferon
 
|Fiblaferon
 +
|-
 
|Frone
 
|Frone
−
|-
 
 
|Finnferon-Alpha
 
|Finnferon-Alpha
 
|Heberon Alfa R
 
|Heberon Alfa R
Line 48: Line 53:
 
|IFN Alpha
 
|IFN Alpha
 
|Imufor
 
|Imufor
−
|-
 
 
|Imukin
 
|Imukin
 
|INF
 
|INF
 +
|-
 
|Inferax
 
|Inferax
 
|Infergen
 
|Infergen
 
|Inmutag
 
|Inmutag
−
|-
 
 
|Interfero
 
|Interfero
 
|Interferon Alfanative
 
|Interferon Alfanative
Line 62: Line 66:
 
|-
 
|-
 
|Interferonum Leucocyticum
 
|Interferonum Leucocyticum
−
|Laroferon
+
|Intron-A
 +
|IntronA
 
|Multiferon
 
|Multiferon
 
|Namalvin
 
|Namalvin
 
|OIF
 
|OIF
−
|-
 
 
|Polyferon
 
|Polyferon
 
|Realdiron
 
|Realdiron
 +
|-
 
|Roceron-A
 
|Roceron-A
 
|Sumiferon
 
|Sumiferon
−
|Wellferon
 
 
|-
 
|-
 
|}
 
|}
Line 84: Line 88:
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
  
−
[[Category:Immunotherapy]]
+
[[Category:Interferon alfas]]
−
[[Category:Interferons]]
 
  
−
[[Category:Chronic myelogenous leukemia medications]]
+
[[Category:Adult T-cell leukemia-lymphoma medications]]
 +
[[Category:Chronic myeloid leukemia medications]]
 +
[[Category:Hairy cell leukemia medications]]
 +
[[Category:Kaposi sarcoma medications]]
 
[[Category:Melanoma medications]]  
 
[[Category:Melanoma medications]]  
−
[[Category:Multiple myeloma medications]]
 
 
[[Category:Neuroendocrine tumor medications]]
 
[[Category:Neuroendocrine tumor medications]]
 
[[Category:Pancreatic NET medications]]
 
[[Category:Pancreatic NET medications]]
−
[[Category:Renal cancer medications]]
+
[[Category:Renal_cell_carcinoma medications]]
 
[[Category:Systemic mastocytosis medications]]
 
[[Category:Systemic mastocytosis medications]]
  
−
[[Category:Drugs FDA approved in 1986]]
+
[[Category:Follicular lymphoma medications (historic)]]
 +
[[Category:Melanoma medications (historic)]]
 +
[[Category:Multiple myeloma medications (historic)]]
 +
 
 +
[[Category:FDA approved in 1986]]

Revision as of 23:31, 2 September 2023

General information

Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. Mechanism not fully understood.[1][2][3]
Route: SC, IM, IV, intralesional
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with hairy cell leukemia. (Based on Golomb et al. 1988)
  • Uncertain date: Indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. (Based on ECOG E1684 & ECOG E1690)
  • Uncertain date: Indicated for the initial treatment of clinically aggressive follicular Non-Hodgkin’s Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin’s Lymphoma has not been demonstrated. (Based on GELA GELF-86)
  • Uncertain date: Indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. (Based on Lane et al. 1988 & Volberding et al. 1987)

Also known as

Caution, may also contain names for interferon beta, interferon gamma, or interferon alfa-2a.

  • Brand names:
Synonyms
Advaferon Alfaferone Biogamma Canferon A Cytoferon Egiferon Feron Fiblaferon
Frone Finnferon-Alpha Heberon Alfa R Humoferon IFN Alpha Imufor Imukin INF
Inferax Infergen Inmutag Interfero Interferon Alfanative Interferon Human Interferon Leucocyticum Interferon Lymphoblastoid
Interferonum Leucocyticum Intron-A IntronA Multiferon Namalvin OIF Polyferon Realdiron
Roceron-A Sumiferon

References

  1. ↑ 1.0 1.1 1.2 Interferon alfa-2b (Intron-A) package insert
  2. ↑ Interferon alfa-2b (Intron-A) package insert (locally hosted backup)
  3. ↑ Intron-A manufacturer's website
  4. ↑ Interferon alfa-2b (Intron-A) patient drug information (Chemocare)
  5. ↑ Interferon alfa-2b (Intron-A) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Interferon_alfa-2b_(Intron-A)&oldid=77145"